ADDLF: AI 评分 45/100 — AI 分析 (4月 2026)

AddLife AB (publ) is a Swedish company that provides equipment, medical devices, and reagents to the healthcare sector, research institutions, and industries. The company operates through Labtech and Medtech segments, serving markets across Europe and internationally.

Key Facts: AI Score: 45/100 Sector: Healthcare

公司概况

概要：

AddLife AB (publ) is a Sweden-based independent player in the European life science market, providing high-quality products, services, and advice to both the private and public sectors, primarily within diagnostics, biomedical research, and medical technology. The company operates through two segments: Labtech and Medtech.

ADDLF是做什么的？

Founded in 1906 and headquartered in Stockholm, Sweden, AddLife AB (publ) has evolved into a prominent player in the European life science market. The company operates through two primary segments: Labtech and Medtech. The Labtech segment focuses on providing products, solutions, and services in diagnostics, biomedical research, and laboratory equipment. This includes offerings for haematology, pathology, point-of-care diagnostics, cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, consumables, and analytical instruments. The segment also provides support, maintenance, advice, and training services. The Medtech segment offers medical device products for surgery, respiration, intensive care, wound care, enteral nutrition, fall prevention, welfare technology, ear, nose, and throat segments, as well as bathroom-related assistive devices and assistive devices for children with disabilities. AddLife serves a diverse customer base, including healthcare systems, research institutions, colleges, universities, and the food and pharmaceutical industries. Geographically, AddLife has a strong presence in Sweden, Finland, Denmark, Norway, the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, and other European countries, as well as operating internationally.

ADDLF的投资论点是什么？

AddLife AB presents a notable market position within the healthcare sector, driven by its diversified product portfolio and strategic market positioning. With a market capitalization of $4.93 billion and a P/E ratio of 30.31, the company exhibits solid financial metrics. The company's growth is supported by increasing demand for advanced medical devices and laboratory equipment, particularly in diagnostics and biomedical research. A key value driver is AddLife's ability to expand its market share through strategic acquisitions and partnerships, enhancing its product offerings and geographic reach. The company's beta of 1.79 indicates higher volatility compared to the market, which investors may want to research. The dividend yield of 0.54% provides a modest income stream. However, potential risks include intense competition and evolving regulatory landscapes within the healthcare industry.

ADDLF在哪个行业运营？

AddLife AB operates within the medical instruments and supplies industry, which is characterized by continuous innovation, stringent regulatory requirements, and increasing demand for advanced healthcare solutions. The global medical devices market is projected to reach trillions of dollars by 2026, driven by an aging population, rising chronic diseases, and technological advancements. AddLife competes with other major players in the industry, focusing on specialized segments such as diagnostics, biomedical research, and medical technology. The company's success depends on its ability to adapt to changing market dynamics, maintain product quality, and expand its geographic presence.

Medical - Instruments & Supplies

Healthcare

ADDLF有哪些增长机遇？

Expansion in Diagnostics: AddLife can capitalize on the growing demand for advanced diagnostic solutions. The global diagnostics market is expected to reach $100 billion by 2027, driven by the need for early disease detection and personalized medicine. AddLife's Labtech segment is well-positioned to benefit from this trend, offering a range of diagnostic products and services. By investing in R&D and strategic partnerships, AddLife can expand its market share and enhance its competitive advantage in the diagnostics sector. Timeline: Ongoing.
Strategic Acquisitions: AddLife can pursue strategic acquisitions to expand its product portfolio and geographic reach. The medical instruments and supplies industry is highly fragmented, offering numerous opportunities for consolidation. By acquiring complementary businesses, AddLife can strengthen its market position and achieve economies of scale. The company has a track record of successful acquisitions, demonstrating its ability to integrate new businesses and generate synergies. Timeline: Ongoing.
Growth in Biomedical Research: The increasing investment in biomedical research presents a significant growth opportunity for AddLife. The global biomedical research market is expected to reach $200 billion by 2028, driven by the need for new treatments and therapies. AddLife's Labtech segment offers a range of products and services for biomedical research, including laboratory equipment, reagents, and consumables. By expanding its offerings and targeting key research institutions, AddLife can capitalize on this growing market. Timeline: Ongoing.
Penetration of Emerging Markets: AddLife can expand its presence in emerging markets, where healthcare spending is increasing rapidly. Countries such as China, India, and Brazil offer significant growth opportunities for medical device companies. By establishing local partnerships and adapting its products to meet local needs, AddLife can penetrate these markets and diversify its revenue streams. Timeline: 3-5 years.
Focus on Welfare Technology: AddLife can leverage the increasing demand for welfare technology solutions, driven by the aging population and the need for assistive devices. The welfare technology market is expected to reach $30 billion by 2029, offering significant growth potential for AddLife's Medtech segment. By developing innovative products and targeting key customer segments, AddLife can establish a strong position in the welfare technology market. Timeline: 2-4 years.

Market Cap of $4.93B indicates a substantial company size within the medical instruments and supplies industry.
P/E ratio of 30.31 suggests investors are paying a premium for AddLife's earnings, reflecting growth expectations.
Profit Margin of 5.4% demonstrates the company's ability to generate profit from its revenue.
Gross Margin of 38.1% indicates the efficiency of AddLife's production and supply chain management.
Dividend Yield of 0.54% provides a small income stream for investors, although it is relatively low compared to other dividend-paying stocks.

ADDLF提供哪些产品和服务？

Provides equipment, medical devices, and reagents to the healthcare system.
Offers products and services for diagnostics and biomedical research.
Supplies laboratory equipment for haematology, pathology, and point-of-care diagnostics.
Offers medical device products for surgery, respiration, and intensive care.
Provides wound care, enteral nutrition, and fall prevention solutions.
Offers assistive devices for children with disabilities.
Provides support, maintenance, advice, and training services.

ADDLF如何赚钱？

Sells equipment, medical devices, and reagents to healthcare providers, research institutions, and industries.
Generates revenue through the Labtech segment by offering diagnostic and biomedical research solutions.
Generates revenue through the Medtech segment by providing medical device products.
Provides support, maintenance, and training services for its products.

Healthcare systems
Research institutions
Colleges and universities
Food and pharmaceutical industries

Strong market position in the European life science market.
Diversified product portfolio across Labtech and Medtech segments.
Established relationships with key customers and suppliers.
Expertise in providing specialized solutions and services.

什么因素可能推动ADDLF股价上涨？

Ongoing: Expansion in the diagnostics market driven by increasing demand for early disease detection.
Ongoing: Strategic acquisitions to expand product portfolio and geographic reach.
Ongoing: Growth in biomedical research driven by increasing investment in new treatments and therapies.
Upcoming: Potential partnerships with key research institutions to enhance product offerings.
Upcoming: New product launches in welfare technology to address the needs of the aging population.

ADDLF的主要风险是什么？

Potential: Intense competition from larger medical device companies.
Potential: Evolving regulatory landscape in the healthcare industry.
Potential: Economic downturns affecting healthcare spending.
Potential: Technological advancements rendering existing products obsolete.
Ongoing: Currency fluctuations affecting international operations.

ADDLF的核心优势是什么？

Diversified product portfolio across Labtech and Medtech segments.
Strong presence in the European life science market.
Established relationships with key customers and suppliers.
Expertise in providing specialized solutions and services.

ADDLF的劣势是什么？

Dependence on the healthcare industry, which is subject to regulatory changes.
Exposure to currency fluctuations, as the company operates internationally.
Limited presence in emerging markets compared to larger competitors.
High beta value indicating higher volatility.

ADDLF有哪些机遇？

Expansion in diagnostics and biomedical research.
Strategic acquisitions to expand product portfolio and geographic reach.
Penetration of emerging markets with increasing healthcare spending.
Leveraging welfare technology to address the needs of the aging population.

ADDLF面临哪些威胁？

Intense competition from larger medical device companies.
Evolving regulatory landscape in the healthcare industry.
Economic downturns affecting healthcare spending.
Technological advancements rendering existing products obsolete.

ADDLF的竞争对手是谁？

Ahlstrom-Munksjo Oyj — Focuses on fiber-based solutions. — (AHICF)
Akebia Therapeutics Inc — Develops therapeutics for kidney disease. — (AKBLF)
Coloplast A/S — Specializes in intimate healthcare products. — (CLCGY)
Cosmo Pharmaceuticals NV — Focuses on gastrointestinal diseases. — (CSMYF)
Chemometec A/S — Develops cell counting solutions. — (CZMWF)

Key Metrics

MoonshotScore: 45/100

Company Profile

CEO: Fredrik Dalborg
Headquarters: Stockholm, SE
Employees: 2,251
Founded: 2018

AI Insight

AI analysis pending for ADDLF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does AddLife AB (publ) do?

AddLife AB (publ) operates in the life science sector, providing a wide array of products, services, and solutions. The company is divided into two main segments: Labtech and Medtech. Labtech focuses on diagnostics, biomedical research, and laboratory equipment, offering products for areas like haematology, pathology, and genetics. Medtech provides medical device products for surgery, respiration, intensive care, and wound care. AddLife serves healthcare systems, research institutions, and the food and pharmaceutical industries across Europe and internationally.

What do analysts say about ADDLF stock?

AI analysis is pending for ADDLF, so a comprehensive analyst consensus is not currently available. However, key valuation metrics include a market capitalization of $4.93 billion and a P/E ratio of 30.31. The company's growth is supported by its diversified product portfolio and strategic market positioning in the European life science market. Investors should monitor the company's financial performance, market trends, and competitive landscape to assess its growth potential and investment risks.

What are the main risks for ADDLF?

AddLife AB faces several risks, including intense competition from larger medical device companies, evolving regulatory requirements in the healthcare industry, and potential economic downturns affecting healthcare spending. The company's international operations expose it to currency fluctuations, and technological advancements could render existing products obsolete. Additionally, as an OTC-traded stock, ADDLF carries risks associated with lower liquidity and less regulatory oversight compared to exchange-listed companies.